Zelboraf Tripped Up By Cost At NICE; Can Better Survival Estimates Save It?
This article was originally published in The Pink Sheet Daily
Executive Summary
Despite being convinced of its clinical effectiveness, NICE demands more data on Roche’s melanoma drug Zelboraf to prove its cost-effectiveness.